Hostname: page-component-89b8bd64d-7zcd7 Total loading time: 0 Render date: 2026-05-12T11:41:19.820Z Has data issue: false hasContentIssue false

Pharmacotherapy of Social Phobia

A Controlled Study with Moclobemide and Phenelzine

Published online by Cambridge University Press:  02 January 2018

M. Versiani*
Affiliation:
Institute of Psychiatry, Federal University of Rio de Janeiro
A. E. Nardi
Affiliation:
Institute of Psychiatry, Federal University of Rio de Janeiro
F. D. Mundim
Affiliation:
Institute of Psychiatry, Federal University of Rio de Janeiro
A. B. Alves
Affiliation:
Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Brazil
M. R. Liebowitz
Affiliation:
New York State Psychiatric Institute and Department of Clinical Psychiatry, College of Physicians and Surgeons, Columbia University, New York, USA
R. Amrein
Affiliation:
4002 Basle, Switzerland
*
Av. N. Sa. Copacabana, 1133/1303, CEP 22070, Rio de Janeiro-RJ, Brazil

Abstract

In a double-blind, parallel group trial, 78 subjects with social phobia received moclobemide (a new reversible inhibitor of monoamine oxidase A) phenelzine, or placebo. After eight weeks, both active drugs – phenelzine somewhat more than moclobemide – were clinically and statistically significantly more effective than placebo, as assessed by rating scales. There was some further improvement between weeks 8 and 16, particularly in the moclobemide group; at week 16, 82% of the moclobemide and 91% of the phenelzine-treated patients were almost asymptomatic. Moclobemide was, however, much better tolerated than phenelzine. Patients withdrawn from active drugs had relapsed by week 24, providing additional support for the efficacy of the active drugs.

Information

Type
Papers
Copyright
Copyright © 1992 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.